RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study
Objective To evaluate the effect of a pharmacist-led intervention on CV risk in patients with inflammatory conditions.Methods Design Prospective pre–postintervention.Setting 17 community pharmacies across Alberta.Population Adults with inflammatory conditions (rheumatoid arthritis, psoriatic arthrit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/3/e043612.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846162181962334208 |
|---|---|
| author | Ross Tsuyuki Carlo Marra Yazid N Al Hamarneh Robert Gniadecki Stephanie Keeling Andrea Morgan |
| author_facet | Ross Tsuyuki Carlo Marra Yazid N Al Hamarneh Robert Gniadecki Stephanie Keeling Andrea Morgan |
| author_sort | Ross Tsuyuki |
| collection | DOAJ |
| description | Objective To evaluate the effect of a pharmacist-led intervention on CV risk in patients with inflammatory conditions.Methods Design Prospective pre–postintervention.Setting 17 community pharmacies across Alberta.Population Adults with inflammatory conditions (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, systemic lupus erythematosus, psoriasis vulgaris) who had at least one uncontrolled risk factor (A1C, blood pressure, LDL-cholesterol or current tobacco users).Intervention All patients enrolled in the study received: physical and laboratory assessment, individualised CV risk assessment and education regarding this risk, treatment recommendations, prescription adaptation and prescribing where necessary to meet treatment targets, regular communication with the patient’s treating physician(s) and regular follow-up with all patients every month for 6 months.Outcomes Primary: change in estimated CV risk (risk of a major CV event in the next 10 years) after 6 months. Secondary: change in individual risk factors (blood pressure, LDL-cholesterol, A1C and tobacco cessation) over a 6-month period.Results We enrolled 99 patients. The median age was 66.41 years (IQR 57.64–72.79), More than half of them (61%) were female and more than three-quarters (86%) were Caucasians. After adjusting for age, sex and ethnicity and centre effect, there was a reduction of 24.5% in CV risk (p<0.001); including a reduction of 0.3 mmol/L in LDL-c (p<0.001), 10.7 mm Hg in systolic blood pressure (p<0.001), 1.25% in A1C (p<0.001). There was a non-significant trend towards tobacco cessation.Conclusion This is the first study on CV risk reduction in patients with inflammatory conditions in a community pharmacy setting. RxIALTA provides evidence for the benefit of pharmacist care on global cardiovascular risk reduction as well as the individual cardiovascular risk factors in patients with inflammatory conditions.Trial registration number NCT03152396. |
| format | Article |
| id | doaj-art-83027f7505e74c33a04afcc015814d8f |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-83027f7505e74c33a04afcc015814d8f2024-11-20T17:00:08ZengBMJ Publishing GroupBMJ Open2044-60552021-03-0111310.1136/bmjopen-2020-043612RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention studyRoss Tsuyuki0Carlo Marra1Yazid N Al Hamarneh2Robert Gniadecki3Stephanie Keeling4Andrea Morgan5Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, CanadaSchool of Pharmacy, University of Otago Division of Health Sciences, Dunedin, New ZealandEPICORE Centre, University of Alberta, Edmonton, Alberta, CanadaMedicine, University of Alberta, Edmonton, Alberta, CanadaUniversity of Alberta, Edmonton, CanadaFoothills Medical Centre, Calgary, Alberta, CanadaObjective To evaluate the effect of a pharmacist-led intervention on CV risk in patients with inflammatory conditions.Methods Design Prospective pre–postintervention.Setting 17 community pharmacies across Alberta.Population Adults with inflammatory conditions (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout, systemic lupus erythematosus, psoriasis vulgaris) who had at least one uncontrolled risk factor (A1C, blood pressure, LDL-cholesterol or current tobacco users).Intervention All patients enrolled in the study received: physical and laboratory assessment, individualised CV risk assessment and education regarding this risk, treatment recommendations, prescription adaptation and prescribing where necessary to meet treatment targets, regular communication with the patient’s treating physician(s) and regular follow-up with all patients every month for 6 months.Outcomes Primary: change in estimated CV risk (risk of a major CV event in the next 10 years) after 6 months. Secondary: change in individual risk factors (blood pressure, LDL-cholesterol, A1C and tobacco cessation) over a 6-month period.Results We enrolled 99 patients. The median age was 66.41 years (IQR 57.64–72.79), More than half of them (61%) were female and more than three-quarters (86%) were Caucasians. After adjusting for age, sex and ethnicity and centre effect, there was a reduction of 24.5% in CV risk (p<0.001); including a reduction of 0.3 mmol/L in LDL-c (p<0.001), 10.7 mm Hg in systolic blood pressure (p<0.001), 1.25% in A1C (p<0.001). There was a non-significant trend towards tobacco cessation.Conclusion This is the first study on CV risk reduction in patients with inflammatory conditions in a community pharmacy setting. RxIALTA provides evidence for the benefit of pharmacist care on global cardiovascular risk reduction as well as the individual cardiovascular risk factors in patients with inflammatory conditions.Trial registration number NCT03152396.https://bmjopen.bmj.com/content/11/3/e043612.full |
| spellingShingle | Ross Tsuyuki Carlo Marra Yazid N Al Hamarneh Robert Gniadecki Stephanie Keeling Andrea Morgan RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study BMJ Open |
| title | RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study |
| title_full | RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study |
| title_fullStr | RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study |
| title_full_unstemmed | RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study |
| title_short | RxIALTA: evaluating the effect of a pharmacist-led intervention on CV risk in patients with chronic inflammatory diseases in a community pharmacy setting: a prospective pre–post intervention study |
| title_sort | rxialta evaluating the effect of a pharmacist led intervention on cv risk in patients with chronic inflammatory diseases in a community pharmacy setting a prospective pre post intervention study |
| url | https://bmjopen.bmj.com/content/11/3/e043612.full |
| work_keys_str_mv | AT rosstsuyuki rxialtaevaluatingtheeffectofapharmacistledinterventiononcvriskinpatientswithchronicinflammatorydiseasesinacommunitypharmacysettingaprospectiveprepostinterventionstudy AT carlomarra rxialtaevaluatingtheeffectofapharmacistledinterventiononcvriskinpatientswithchronicinflammatorydiseasesinacommunitypharmacysettingaprospectiveprepostinterventionstudy AT yazidnalhamarneh rxialtaevaluatingtheeffectofapharmacistledinterventiononcvriskinpatientswithchronicinflammatorydiseasesinacommunitypharmacysettingaprospectiveprepostinterventionstudy AT robertgniadecki rxialtaevaluatingtheeffectofapharmacistledinterventiononcvriskinpatientswithchronicinflammatorydiseasesinacommunitypharmacysettingaprospectiveprepostinterventionstudy AT stephaniekeeling rxialtaevaluatingtheeffectofapharmacistledinterventiononcvriskinpatientswithchronicinflammatorydiseasesinacommunitypharmacysettingaprospectiveprepostinterventionstudy AT andreamorgan rxialtaevaluatingtheeffectofapharmacistledinterventiononcvriskinpatientswithchronicinflammatorydiseasesinacommunitypharmacysettingaprospectiveprepostinterventionstudy |